{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T10:41:44Z","timestamp":1773744104134,"version":"3.50.1"},"reference-count":42,"publisher":"Walter de Gruyter GmbH","issue":"2","funder":[{"name":"University of Malta Research GrantN\/A","award":["PHRRP12-19"],"award-info":[{"award-number":["PHRRP12-19"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_dmpt-2021-0160_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      The cytochrome P450 2C19\n                      <jats:italic>*2<\/jats:italic>\n                      (\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      ) genetic polymorphism is associated with reduced clopidogrel bioactivation, increasing the risk of atherothrombotic complications after percutaneous coronary intervention (PCI). In-stent restenosis (ISR) is a complication that limits the long-term prognosis of PCI. The aim was to investigate the association between presence of the\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      allele and ISR within one-year after PCI in patients prescribed dual antiplatelet therapy with aspirin and clopidogrel.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2021-0160_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Sixty patients with angiographically-confirmed drug eluting stent (DES)-ISR within 12\u00a0months post-PCI when on DAPT with aspirin and clopidogrel were retrospectively identified (Cases). Another 60 patients with no documented ISR post-PCI in the study period (Controls) were case-matched for age, gender, ethnicity, diabetes mellitus and estimated glomerular filtration rate value, and were invited for\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      genotyping. The association between presence of the\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      allele and ISR was analysed using the Fisher\u2019s exact test and binary logistic regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2021-0160_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty-six (43.3%) cases and 5 (8.3%) controls were carriers of one or two\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      alleles. As to non-carrier status of the\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      allele, 34 (56.7%) cases and 55 (91.7%) controls were identified. The association between\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      carrier status and DES-ISR within one-year post-PCI was statistically significant (p&lt;0.001) in both the univariate and multivariate analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_dmpt-2021-0160_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The proportion of patients who were carriers of one or two\n                      <jats:italic>CYP2C19*2<\/jats:italic>\n                      alleles who presented with DES-ISR within one-year post-PCI while on clopidogrel was significantly higher compared to patients with no documented ISR.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/dmpt-2021-0160","type":"journal-article","created":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T11:02:32Z","timestamp":1638356552000},"page":"155-161","source":"Crossref","is-referenced-by-count":3,"title":["<i>CYP2C19*2<\/i>\n                    genetic polymorphism and incidence of in-stent restenosis in patients on clopidogrel: a matched case-control study"],"prefix":"10.1515","volume":"37","author":[{"given":"Sara","family":"Osama","sequence":"first","affiliation":[{"name":"Department of Pharmacy , Faculty of Medicine and Surgery, University of Malta , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-2363","authenticated-orcid":false,"given":"Francesca","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Faculty of Medicine and Surgery, University of Malta , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graziella","family":"Zahra","sequence":"additional","affiliation":[{"name":"Department of Pathology , Molecular Diagnostics Unit, Mater Dei Hospital , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Barbara","sequence":"additional","affiliation":[{"name":"Department of Pathology , Molecular Diagnostics Unit, Mater Dei Hospital , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert G.","family":"Xuereb","sequence":"additional","affiliation":[{"name":"Department of Cardiology , Mater Dei Hospital , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liberato","family":"Camilleri","sequence":"additional","affiliation":[{"name":"Department of Statistics and Operations Research , Faculty of Science, University of Malta , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian M.","family":"Azzopardi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy , Faculty of Medicine and Surgery, University of Malta , Msida , Malta"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"2025121207074424746_j_dmpt-2021-0160_ref_001","doi-asserted-by":"crossref","unstructured":"Capodanno, D, Alfonso, F, Levine, GN, Valgimigli, M, Angiolillo, DJ. ACC\/AHA vs. ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 2018;72:2915\u201331. https:\/\/doi.org\/10.1016\/j.jacc.2018.09.057.","DOI":"10.1016\/j.jacc.2018.09.057"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_002","doi-asserted-by":"crossref","unstructured":"Sangkuhl, K, Klein, TE, Altman, RB. Clopidogrel pathway. Pharmacogenetics Genom 2010;20:463\u20135. https:\/\/doi.org\/10.1097\/fpc.0b013e3283385420.","DOI":"10.1097\/FPC.0b013e3283385420"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_003","doi-asserted-by":"crossref","unstructured":"Aradi, D, Kom\u00f3csi, A, Vorobcsuk, A, Rideg, O, Tok\u00e9s-F\u00fczesi, M, Magyarlaki, T, et al.. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 2010;160:543\u201351. https:\/\/doi.org\/10.1016\/j.ahj.2010.06.004.","DOI":"10.1016\/j.ahj.2010.06.004"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_004","doi-asserted-by":"crossref","unstructured":"Scott, SA, Sangkuhl, K, Stein, CM, Hulot, JS, Mega, JL, Roden, DM, et al.. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 2013;94:317\u201323. https:\/\/doi.org\/10.1038\/clpt.2013.105.","DOI":"10.1038\/clpt.2013.105"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_005","doi-asserted-by":"crossref","unstructured":"Dangas, GD, Claessen, BE, Caixeta, A, Sanidas, EA, Mintz, GS, Mehran, R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol 2010;56:1897\u2013907. https:\/\/doi.org\/10.1016\/j.jacc.2010.07.028.","DOI":"10.1016\/j.jacc.2010.07.028"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_006","doi-asserted-by":"crossref","unstructured":"Nozari, Y, Vosooghi, S, Boroumand, M, Poorhosseini, H, Nematipour, E, Salarifar, M, et al.. The impact of cytochrome P450 2C19 polymorphism on the occurrence of one-year in-stent restenosis in patients who underwent percutaneous coronary intervention: a case-match study. Anatol J Cardiol 2015;15:348\u201353. https:\/\/doi.org\/10.5152\/akd.2014.5418.","DOI":"10.5152\/akd.2014.5418"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_007","doi-asserted-by":"crossref","unstructured":"Wirth, F, Zahra, G, Xuereb, RG, Barbara, C, Camilleri, L, Fenech, A, et al.. CYP2C19*2 allele carrier status and coronary in-stent restenosis: is there an association? J Explor Res Pharmacol 2018;3:55\u201360. https:\/\/doi.org\/10.14218\/jerp.2018.00002.","DOI":"10.14218\/JERP.2018.00002"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_008","doi-asserted-by":"crossref","unstructured":"Ruedlinger, J, Prado, Y, Zambrano, T, Saavedra, N, Bobadilla, B, Potthoff, M, et al.. CYP2C19*2 polymorphism in Chilean patients with in-stent restenosis development and controls. Biomed Res Int 2017;2017:5783719. https:\/\/doi.org\/10.1155\/2017\/5783719.","DOI":"10.1155\/2017\/5783719"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_009","doi-asserted-by":"crossref","unstructured":"Zhang, M, Wang, J, Zhang, Y, Zhang, P, Jia, Z, Ren, M, et al.. Impacts of CYP2C19 polymorphism and clopidogrel dosing on in-stent restenosis: a retrospective cohort study in Chinese patients. Drug Des Dev Ther 2020;14:669\u201376. https:\/\/doi.org\/10.2147\/dddt.s242167.","DOI":"10.2147\/DDDT.S242167"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_010","doi-asserted-by":"crossref","unstructured":"Singh, M, Gersh, BJ, McClelland, RL, Ho, KKL, Willerson, JT, Penny, WF, et al.. Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the prevention of restenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2004;109:2727\u201331. https:\/\/doi.org\/10.1161\/01.cir.0000131898.18849.65.","DOI":"10.1161\/01.CIR.0000131898.18849.65"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_011","doi-asserted-by":"crossref","unstructured":"Taniwaki, M, Stefanini, GG, Silber, S, Richardt, G, Vranckx, P, Serruys, PW, et al.. Four-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A\u00a0randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention). J Am Coll Cardiol 2014;63:1617\u201325. https:\/\/doi.org\/10.1016\/j.jacc.2013.12.036.","DOI":"10.1016\/j.jacc.2013.12.036"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_012","unstructured":"Wang, JL, Qin, Z, Wang, ZJ, Shi, DM1, Liu, YY, Zhao, YX, et al.. New predictors of in-stent restenosis in patients with diabetes mellitus undergoing percutaneous coronary intervention with drug-eluting stent. J Geriatr Cardiol 2018;15:137\u201345. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2018.02.011."},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_013","doi-asserted-by":"crossref","unstructured":"Kang, J, Cho, YS, Kim, SW, Park, JJ, Yoon, YE, Oh, IY, et al.. Intravascular ultrasound and angiographic predictors of in-stent restenosis of chronic total occlusion lesions. PLoS One 2015;10:e0140421. https:\/\/doi.org\/10.1371\/journal.pone.0140421.","DOI":"10.1371\/journal.pone.0140421"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_014","doi-asserted-by":"crossref","unstructured":"Ma, S, Yang, D, Zhang, X, Tang, B, Li, D, Sun, M, et al.. Comparison of restenosis rate with sirolimus-eluting stent in STEMI patients with and without diabetes at six-month angiographic follow-up. Acta Cardiol 2011;66:603\u20136. https:\/\/doi.org\/10.1080\/ac.66.5.2131085.","DOI":"10.1080\/AC.66.5.2131085"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_015","doi-asserted-by":"crossref","unstructured":"Kundi, H, Korkmaz, A, Balun, A, Cicekcioglu, H, Kiziltunc, E, Gursel, K, et al.. Is in-stent restenosis after a successful coronary stent implantation due to stable angina associated with TG\/HDL-C ratio? Angiology 2017;68:7. https:\/\/doi.org\/10.1177\/0003319716689366.","DOI":"10.1177\/0003319716689366"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_016","doi-asserted-by":"crossref","unstructured":"Mohan, S, Dhall, A. A comparative study of restenosis rates in bare metal and drug-eluting stents. Int J Angiol 2010;19:66\u201372. https:\/\/doi.org\/10.1055\/s-0031-1278368.","DOI":"10.1055\/s-0031-1278368"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_017","doi-asserted-by":"crossref","unstructured":"Hu, R, Liu, J, Zhou, Y, Hu, B. Association of smoking with restenosis and major adverse cardiac events after coronary stenting: a meta-analysis. Pak J Med Sci 2015;31:1002\u20138. https:\/\/doi.org\/10.12669\/pjms.314.7495.","DOI":"10.12669\/pjms.314.7495"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_018","doi-asserted-by":"crossref","unstructured":"Cassese, S, Xu, B, Habara, S, Rittger, H, Byrne, RA, Waliszewski, M, et al.. Incidence and predictors of reCurrent restenosis after drug-coated balloon angioplasty for restenosis of a drUg-eluting stent: the ICARUS Cooperation. Rev Esp Cardiol 2018;71:620\u20137. https:\/\/doi.org\/10.1016\/j.rec.2017.08.005.","DOI":"10.1016\/j.rec.2017.08.005"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_019","doi-asserted-by":"crossref","unstructured":"Hasdai, D, Garratt, KN, Grill, DE, Lerman, A, Holmes, DRJr. Effect of smoking status on the long-term outcome after successful percutaneous coronary revascularization. N Engl J Med 1997;336:755\u201361. https:\/\/doi.org\/10.1056\/nejm199703133361103.","DOI":"10.1056\/NEJM199703133361103"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_020","doi-asserted-by":"crossref","unstructured":"Cohen, DJ, Doucet, M, Cutlip, DE, Ho, KK, Popma, JJ, Kuntz, RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker\u2019s paradox? Circulation 2001;104:773\u20138. https:\/\/doi.org\/10.1161\/hc3201.094225.","DOI":"10.1161\/hc3201.094225"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_021","doi-asserted-by":"crossref","unstructured":"Gurbel, PA, Bliden, KP, Logan, DK, Kereiakes, DJ, Lasseter, KC, White, A, et al.. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. J Am Coll Cardiol 2013;62:505\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2013.03.037.","DOI":"10.1016\/j.jacc.2013.03.037"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_022","doi-asserted-by":"crossref","unstructured":"Tocci, G, Barbato, E, Coluccia, R, Modestino, A, Pagliaro, B, Mastromarino, V, et al.. Blood pressure levels at the time of percutaneous coronary revascularization and risk of coronary in-stent restenosis. Am J Hypertens 2016;29:509\u201318. https:\/\/doi.org\/10.1093\/ajh\/hpv131.","DOI":"10.1093\/ajh\/hpv131"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_023","doi-asserted-by":"crossref","unstructured":"Wan, YL, Tsay, PK, Chen, CC, Juan, YH, Huang, YC, Chan, WH, et al.. Coronary in-stent restenosis: predisposing clinical and stent-related factors, diagnostic performance and analyses of inaccuracies in 320-row computed tomography angiography. Int J Cardiovasc Imag 2016;32:105\u201315. https:\/\/doi.org\/10.1007\/s10554-016-0872-6.","DOI":"10.1007\/s10554-016-0872-6"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_024","doi-asserted-by":"crossref","unstructured":"Qian, H, Luo, Z, Xiao, C, Chen, J, Li, D, Xu, H, et al.. Red cell distribution width in coronary heart disease: prediction of restenosis and its relationship with inflammatory markers and lipids. Postgrad Med J 2018;94:489\u201394. https:\/\/doi.org\/10.1136\/postgradmedj-2018-135806.","DOI":"10.1136\/postgradmedj-2018-135806"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_025","doi-asserted-by":"crossref","unstructured":"Tang, L, Cui, QW, Liu, DP, Fu, YY. The number of stents was an independent risk of stent restenosis in patients undergoing percutaneous coronary intervention. Medicine (Baltim) 2019;98:e18312. https:\/\/doi.org\/10.1097\/MD.0000000000018312.","DOI":"10.1097\/MD.0000000000018312"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_026","doi-asserted-by":"crossref","unstructured":"Byrne, RA, Joner, M, Kastrati, A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gr\u00fcntzig lecture ESC 2014. Eur Heart J 2015;36:3320\u201331. https:\/\/doi.org\/10.1093\/eurheartj\/ehv511.","DOI":"10.1093\/eurheartj\/ehv511"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_027","doi-asserted-by":"crossref","unstructured":"Lee, JH, Kim, ED, Jun, EJ, Yoo, HS, Lee, JW. Analysis of trends and prospects regarding stents for human blood vessels. Biomater Res 2018;13:8. https:\/\/doi.org\/10.1186\/s40824-018-0114-1.","DOI":"10.1186\/s40824-018-0114-1"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_028","doi-asserted-by":"crossref","unstructured":"Mercado, N, Boersma, E, Wijns, W, Gersh, BJ, Morillo, CA, de Valk, V, et al.. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol 2001;38:645\u201352. https:\/\/doi.org\/10.1016\/s0735-1097(01)01431-0.","DOI":"10.1016\/S0735-1097(01)01431-0"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_029","doi-asserted-by":"crossref","unstructured":"Wasser, K, Schnaudigel, S, Wohlfahrt, J, Psychogios, MN, Knauth, M, Gr\u00f6schel, K. Inflammation and in-stent restenosis: the role of serum markers and stent characteristics in carotid artery stenting. PLoS One 2011;6:e22683. https:\/\/doi.org\/10.1371\/journal.pone.0022683.","DOI":"10.1371\/journal.pone.0022683"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_030","unstructured":"Wirth, F, Zahra, G, Xuereb, R, Barbara, C, Camilleri, L, Fenech, A, et al.. CYP2C19 genetic polymorphisms in Maltese patients on clopidogrel therapy. Malta Med J 2018;30:14\u201320."},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_031","doi-asserted-by":"crossref","unstructured":"Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, et al.. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011;89:662\u201373. https:\/\/doi.org\/10.1038\/clpt.2011.34.","DOI":"10.1038\/clpt.2011.34"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_032","doi-asserted-by":"crossref","unstructured":"Shuldiner, AR, Palmer, K, Pakyz, RE, Alestock, TD, Maloney, KA, O\u2019Neill, C, et al.. Implementation of pharmacogenetics: the University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet 2014;166C:76\u201384. https:\/\/doi.org\/10.1002\/ajmg.c.31396.","DOI":"10.1002\/ajmg.c.31396"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_033","doi-asserted-by":"crossref","unstructured":"Wirth, F, Zahra, G, Xuereb, RG, Barbara, C, Fenech, A, Azzopardi, LM. Comparison of a rapid point-of-care and two laboratory-based CYP2C19*2 genotyping assays for personalisation of antiplatelet therapy. Int J Clin Pharm 2016;38:414\u201320. https:\/\/doi.org\/10.1007\/s11096-016-0269-6.","DOI":"10.1007\/s11096-016-0269-6"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_034","doi-asserted-by":"crossref","unstructured":"Borse, MS, Dong, OM, Polasek, MJ, Farley, JF, Stouffer, GA, Lee, CR. CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and one-year outcomes following percutaneous coronary intervention. Pharmacogenomics 2017;18:1155\u201366. https:\/\/doi.org\/10.2217\/pgs-2017-0075.","DOI":"10.2217\/pgs-2017-0075"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_035","doi-asserted-by":"crossref","unstructured":"Cavallari, LH, Lee, CR, Beitelshees, AL, Cooper-DeHoff, RM, Duarte, JD, Voora, D, et al.. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2018;11:181\u201391. https:\/\/doi.org\/10.1016\/j.jcin.2017.07.022.","DOI":"10.1016\/j.jcin.2017.07.022"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_036","doi-asserted-by":"crossref","unstructured":"Cavallari, LH, Franchi, F, Rollini, F, Been, L, Rivas, A, Agarwal, M, et al.. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J\u00a0Transl Med 2018;16:92. https:\/\/doi.org\/10.1186\/s12967-018-1469-8.","DOI":"10.1186\/s12967-018-1469-8"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_037","doi-asserted-by":"crossref","unstructured":"Empey, PE, Stevenson, JM, Tuteja, S, Weitzel, KW, Angiolillo, DJ, Beitelshees, AL, et al.. Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 2018;104:664\u201374. https:\/\/doi.org\/10.1002\/cpt.1006.","DOI":"10.1002\/cpt.1006"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_038","doi-asserted-by":"crossref","unstructured":"Lee, CR, Sriramoju, VB, Cervantes, A, Howell, LA, Varunok, N, Madan, S, et al.. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. Circ Genom Precis Med 2018;11:e002069. https:\/\/doi.org\/10.1161\/CIRCGEN.117.002069.","DOI":"10.1161\/CIRCGEN.117.002069"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_039","doi-asserted-by":"crossref","unstructured":"Hulot, JS, Chevalier, B, Belle, L, Cayla, G, Khalife, K, Funck, F, et al.. Routine CYP2C19 genotyping to adjust thienopyridine treatment after primary PCI for STEMI: results of the GIANT Study. JACC Cardiovasc Interv 2020;13:621\u201330. https:\/\/doi.org\/10.1016\/j.jcin.2020.01.219.","DOI":"10.1016\/j.jcin.2020.01.219"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_040","doi-asserted-by":"crossref","unstructured":"Claassens, DM, Ten Berg, JM. Genotype-guided treatment of oral P2Y12 inhibitors: where do we stand? Pharmacogenomics 2020;21:83\u20136. https:\/\/doi.org\/10.2217\/pgs-2019-0162.","DOI":"10.2217\/pgs-2019-0162"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_041","doi-asserted-by":"crossref","unstructured":"Pereira, N, Farkouh, M, So, D, Lennon, R, Geller, N, Mathew, V, et al.. Effect of genotype-guided oral P2Y12 inhibitor selection vs. conventional clopidogrel therapy on ischemic outcomes after percutaneous coronary intervention: the TAILOR-PCI randomized clinical trial. J Am Med Assoc 2020;324:761\u201371. https:\/\/doi.org\/10.1001\/jama.2020.12443.","DOI":"10.1001\/jama.2020.12443"},{"key":"2025121207074424746_j_dmpt-2021-0160_ref_042","doi-asserted-by":"crossref","unstructured":"Kennedy, MJ. Personalized medicines\u00a0\u2013 are pharmacists ready for the challenge? Integrated Pharm Res Pract 2018;7:113\u201323. https:\/\/doi.org\/10.2147\/iprp.s133083.","DOI":"10.2147\/IPRP.S133083"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0160\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0160\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T07:48:28Z","timestamp":1765525708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0160\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":42,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,11,29]]},"published-print":{"date-parts":[[2022,6,23]]}},"alternative-id":["10.1515\/dmpt-2021-0160"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2021-0160","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-456499\/v1","asserted-by":"object"}]},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}